Anavex Life Sciences Corp (AVXL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anavex Life Sciences Corp (AVXL) has a cash flow conversion efficiency ratio of -0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.15 Million) by net assets ($126.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Anavex Life Sciences Corp defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Anavex Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anavex Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anavex Life Sciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacific Current Group Ltd
AU:PAC
|
0.026x |
|
Martifer SGPS S.A
LS:MAR
|
0.099x |
|
Hwacom Systems
TWO:6163
|
0.237x |
|
P.C.B Tec
TA:PCBT
|
0.032x |
|
All Iron Re I Socimi Sa
MC:YAI1
|
0.053x |
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
-0.187x |
|
ZCCM Investments Holdings Plc
PA:MLZAM
|
-0.002x |
|
VNV Global AB
ST:VNV
|
0.007x |
Annual Cash Flow Conversion Efficiency for Anavex Life Sciences Corp (2004–2025)
The table below shows the annual cash flow conversion efficiency of Anavex Life Sciences Corp from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Anavex Life Sciences Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $94.87 Million | $-39.04 Million | -0.412x | -60.64% |
| 2024-09-30 | $120.26 Million | $-30.81 Million | -0.256x | -30.80% |
| 2023-09-30 | $141.85 Million | $-27.79 Million | -0.196x | -15.15% |
| 2022-09-30 | $142.49 Million | $-24.24 Million | -0.170x | +15.57% |
| 2021-09-30 | $150.82 Million | $-30.38 Million | -0.201x | +74.22% |
| 2020-09-30 | $27.24 Million | $-21.29 Million | -0.782x | +14.41% |
| 2019-09-30 | $20.29 Million | $-18.53 Million | -0.913x | -48.71% |
| 2018-09-30 | $20.49 Million | $-12.58 Million | -0.614x | -65.16% |
| 2017-09-30 | $24.25 Million | $-9.02 Million | -0.372x | +74.61% |
| 2016-09-30 | $6.31 Million | $-9.24 Million | -1.464x | -343.71% |
| 2015-09-30 | $12.81 Million | $-4.23 Million | -0.330x | +97.61% |
| 2014-09-30 | $192.63K | $-2.66 Million | -13.806x | -4473.47% |
| 2013-09-30 | $-2.46 Million | $-777.57K | 0.316x | -46.39% |
| 2012-09-30 | $-2.88 Million | $-1.69 Million | 0.589x | -82.31% |
| 2011-09-30 | $-1.14 Million | $-3.80 Million | 3.328x | +114.44% |
| 2010-09-30 | $-2.96 Million | $-4.59 Million | 1.552x | +114.21% |
| 2009-09-30 | $-3.86 Million | $-2.79 Million | 0.724x | -32.88% |
| 2008-09-30 | $-2.29 Million | $-2.47 Million | 1.079x | +53.48% |
| 2007-09-30 | $-462.50K | $-325.25K | 0.703x | -66.36% |
| 2006-09-30 | $-15.51K | $-32.43K | 2.091x | -10.93% |
| 2005-09-30 | $-26.02K | $-61.07K | 2.347x | +605.45% |
| 2004-09-30 | $25.61K | $-11.89K | -0.464x | -- |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more